Troponin I as a Biomarker for Early Detection of Acute Myocardial Infarction

Duque-Ossa, L. C.; García-Ferrera, B.; Reyes-Retana, J.A.

doi:10.1016/j.cpcardiol.2021.101067

Cited by 18 publications

(12 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highly sensitive label-free detection of cTnI was designed to immobilize monoclonal antibodies for cTnI to the SiNWs surface to diagnose acute myocardial infarction. 172 The monitoring was performed by atomic force microscopy (AFM), exhibiting a sensitivity from 5 pg/mL to 5 ng/mL. Moreover, Li et al 173 prepared highly sensitive electrochemical biosensors to detect glucose using a 3D hybrid structure based on a vertically aligned PtNWs array coated with AuNPs-GOx.…”

Section: Magnetic Nanoparticles (Mnps)mentioning

confidence: 99%

Review on Healthcare Biosensing Nanomaterials

Tripathi

Bonilla‐Cruz

2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Fast technological progress has sped up the growth of telemedicine, mobile e-health services, and healthcare monitoring, which, nowadays, are technologies in high demand in the medical field and analytical sensing. Biosensing device design has promoted forefront research topics wherein new sensing technologies have been developed. In this regard, nanomaterials have had a crucial role wherein novel biosensors based on nanomaterials have emerged as detective tools for several biomolecules. Most biosensors are remarkably sensitive and selective to detect cancer biomarkers, toxins in foods, drugs, pathogenic microorganisms, cholesterol, pesticides, nucleic acids, glucose, heavy-metal contaminations, and other bioanalytes under different platforms at extraordinarily low concentrations (nanomolar, picomolar, or femtomolar). A comprehensive review of nanomaterials used for healthcare biosensing is offered herein. Specifically, this review offers a new point of view, highlighting and covering exhaustively several kinds of nanomaterials (<500 nm) to detect human diseases through biosensing. In this sense, we organize them into organic, inorganic, and carbon-based, thus offering a guide to selecting the best nanomaterial for specific detection. Further, it provides a roadmap to the real-time utilization of nanomaterials at a commercial scale. Also, this review addresses some crucial aspects of nanomaterials use and applications for healthcare biosensing. The progress discussed in this paper highlights the immense potential to implement the use of nanomaterials and nanocomposites in the initial examination of diseases and point-of-care testing.

show abstract

Section: Magnetic Nanoparticles (Mnps)mentioning

confidence: 99%

Review on Healthcare Biosensing Nanomaterials

Tripathi

Bonilla‐Cruz

2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Among the most valuable cardiospecific markers recommended for diagnosing myocardial infarction and cardiac failure, the determination of CTs and natriuretic peptides in urine has shown promising results. Recent studies by several research groups have shown the high diagnostic significance of CTs and natriuretic peptides in noninvasively obtained body fluids in individuals with coronary heart disease [ 46 , 95 ], myocardial infarction [ 43 - 45 , 47 , 96 , 97 ], diabetes mellitus [ 45 ], cardiac failure [ 98 , 99 ] and HT [ 54 ]. Further research should be aimed at clarifying these promising diagnostic possibilities.…”

Section: Ht As a Significant Cause Of Increased Cts: Mechanisms Of Mc...mentioning

confidence: 99%

Hypertension as One of the Main Non-Myocardial Infarction-Related Causes of Increased Cardiospecific Troponins: From Mechanisms to Significance in Current Medical Practice

Chaulin

2022

J Clin Med Res

View full text Add to dashboard Cite

It is well known that many pathological conditions of both cardiovascular diseases (CVDs) (coronary heart disease, myocardial infarction, arrhythmias, myocarditis, cardiomyopathy, etc.) and noncardiac (sepsis, anemia, kidney diseases, diabetes mellitus, etc.) origin in the course of their development cause injury to contractile cardiac muscle cells -myocardial cells (MCs). One of the most sensitive and specific criteria for detecting MC injury are cardiospecific troponins (CTs), which are regulatory protein molecules that are released into the blood serum from MC upon their death or injury. Current methods for determining CTs are called high-sensitive ones, and their main advantage is a very low minimum detectable concentration (limit of detection) (average 1 -10 ng/L or less), which allows early detection of minor MC injury at the earliest stages of CVDs, and therefore they can change the understanding of disease development mechanisms and open up new diagnostic possibilities. One of the most common and dangerous early diseases of the cardiovascular system is hypertension (HT). The novelty of this article lies in the discussion of a new diagnostic direction -predicting the risk of developing CVDs and their dangerous complications in patients with HT by determining the concentration of CTs. In addition, pathophysiological mechanisms underlying MC injury and the release of CTs into the bloodstream and the elimination of CTs into the urine are proposed. This information will contribute to additional fundamental and clinical research to verify the new diagnostic possibility of using CTs in clinical practice (for the management of patients with HT).

show abstract

“…A population of at least 300 healthy persons with an adequate age, ethnic, and gender mix is necessary for competent estimation of the 99th percentile URL for a current cTn test, according to recommendations. Because the 99th percentiles in high-sensitivity tests are gender-specific, at least 300 healthy females and 300 healthy men should be examined [46].…”

Section: Measurement Of Assay Per-formancementioning

confidence: 99%

Acute Myocardial Infarction (AMI) Diagnosis; Impact of Technology in Developing Highly Sensitive Biomarkers and Assays

Olatunji¹,

Nduka²

2022

View full text Add to dashboard Cite

Acute myocardial infarction (AMI), a cardiovascular disease have been known to cause high morbidity and mortality rate in several countries. Hence, several serum biomarkers have evolved as a standard and bedrock for its diagnosis one of which is, cardiac troponin. This cardiac biomarker's accurate and rapid detection is critical in reducing the risk of heart attack-related complications. However, the delay experienced in the determination of a patient’s clinical state, coupled with the time of admitting them to the hospital depicts the need for improving diagnosing AMI by developing a highly sensitive biomarker. In this review we discuss, biomarkers and immunoassays employed in diagnosing acute myocardial infarction. Specifically, we reviewed and discussed cardiac troponin, a widely used biomarker. Subsequently, we discuss various methods used in assessing its performance and how technology has helped in developing more sensitive cardiac troponin to fast track its rate of diagnosis. At the end, we propose the integration of several disciplines from nanotechnology to biotechnology to develop a robust medical diagnostic system to facilitate disease diagnosis and help save lives.

show abstract

Troponin I as a Biomarker for Early Detection of Acute Myocardial Infarction

Cited by 18 publications

References 123 publications

Review on Healthcare Biosensing Nanomaterials

Review on Healthcare Biosensing Nanomaterials

Hypertension as One of the Main Non-Myocardial Infarction-Related Causes of Increased Cardiospecific Troponins: From Mechanisms to Significance in Current Medical Practice

Acute Myocardial Infarction (AMI) Diagnosis; Impact of Technology in Developing Highly Sensitive Biomarkers and Assays

Contact Info

Product

Resources

About